As Passed by the Senate

130th General Assembly Regular Session 2013-2014

Sub. H. B. No. 315

Representative Wachtmann 

Cosponsors: Representatives Antonio, Bishoff, Adams, R., Amstutz, Anielski, Ashford, Baker, Barborak, Barnes, Beck, Blair, Blessing, Boose, Brown, Buchy, Burkley, Celebrezze, Cera, Conditt, Derickson, DeVitis, Driehaus, Duffey, Foley, Green, Grossman, Hackett, Hagan, R., Hall, Hayes, Henne, Hill, Huffman, Johnson, Kunze, Landis, Letson, Maag, McClain, Milkovich, O'Brien, Patmon, Patterson, Pelanda, Perales, Pillich, Ramos, Reece, Retherford, Rogers, Rosenberger, Ruhl, Sears, Sheehy, Slaby, Smith, Stautberg, Stebelton, Stinziano, Sykes, Thompson, Williams, Winburn, Young Speaker Batchelder 

Senators Bacon, Balderson, Beagle, Brown, Burke, Cafaro, Eklund, Faber, Gardner, Hite, Hughes, Jones, LaRose, Manning, Obhof, Oelslager, Patton, Peterson, Sawyer, Schaffer, Schiavoni, Seitz, Smith, Tavares, Turner, Uecker, Widener 

---

A BILL

To amend sections 3711.12 and 3719.41 and to enact

1

sections 3711.13 and 3711.30 of the Revised Code

2

to require reports to the Department of Health

3

regarding newborns diagnosed as opioid dependent,

4

to update the chemical name for a type of

5

controlled substance, and to specify procedures

6

for granting variances or waivers of any

7

requirement in the rules governing operation of

8

maternity homes.

9

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 3711.12 and 3719.41 be amended and	10
sections 3711.13 and 3711.30 of the Revised Code be enacted to	11
read as follows:	12

Sec. 3711.12. (A) The director of health shall adopt rules in	13
accordance with Chapter 119. of the Revised Code as the director	14
considers necessary to implement the requirements of this chapter	15
for licensure and operation of maternity units, newborn care	16
nurseries, and maternity homes. The rules shall include provisions	17
for the following:	18

(1) Licensure application forms and procedures;

19

(2) Renewal procedures, including procedures that address the	20
right of the director of health, at the director's sole	21
discretion, to conduct an inspection prior to renewal of a	22
license;	23

(3) Initial license fees and license renewal fees;

24

(4) Fees for inspections conducted by the director under	25
section 3711.10 of the Revised Code;	26

(5) Safety standards, quality-of-care standards, and	27
quality-of-care data reporting requirements;	28

(6) Reporting and auditing requirements;

29

(7) Inspection criteria, procedures, and guidelines;

30

(8) Application forms to be used and procedures to be	31
followed in applying under section 3711.13 of the Revised Code for	32
a variance or waiver of any of the requirements of the rules	33
adopted under this section regarding the operation of a maternity	34
home;	35

(9) Any other rules necessary to implement this chapter.

36

(B) When adopting rules under this section, the director	37
shall give consideration to recommendations regarding obstetric	38
and newborn care issued by the American college of obstetricians	39
and gynecologists; American academy of pediatrics; American	40
academy of family physicians; American society of	41
anesthesiologists; American college of nurse-midwives; United	42
States centers for disease control and prevention; association of	43
women's health, obstetric and neonatal nurses; and association of	44
perioperative registered nurses, or their successor organizations.	45
The director shall also consider the recommendations of the	46
maternity and newborn advisory council established in section	47
3711.20 of the Revised Code.	48

Sec.  3711.13.  (A) A board of health may grant a variance	49
from or waiver of any of the requirements established in rules	50
adopted under section 3711.12 of the Revised Code regarding the	51
operation of a maternity home.	52

(B) Each maternity home seeking a variance or waiver shall	53
file an application with the board of health of the city or	54
general health district in which the maternity home is located.	55
The application shall be made on the form and in accordance with	56
the procedures specified in rules adopted under section 3711.12 of	57
the Revised Code.	58

(C) The board of health shall review all applications	59
received. Not later than forty-five days after receiving an	60
application, the board shall determine whether to grant the	61
variance or waiver and shall notify the applicant in writing of	62
the board's decision.	63

(D) Both of the following apply to a board of health in	64
determining whether to grant a variance or waiver:	65

(1) A variance shall be granted to an applicant if the board	66
determines that the intent of a requirement has been met by the	67
applicant in an alternate manner.	68

(2) A waiver shall be granted if the board determines that	69
strict application of a requirement would cause an undue hardship	70
to the applicant and that granting the waiver would not jeopardize	71
the health and safety of any patient or resident.	72

(E) If a board of health denies a variance or waiver	73
requested by a maternity home, the home may appeal the denial by	74
filing a notice of appeal with the director of health. The notice	75
must be filed not later than thirty days after the board's denial	76
of the request.	77

Not later than forty-five days after the notice of appeal is	78
filed, the director shall either affirm the board's denial or	79
grant the variance or waiver. The director shall notify the board	80
and the maternity home in writing of the director's action.	81

(F) Notwithstanding any other provision of this section, the	82
director may void the board's granting of a waiver or variance	83
issued under this section. The director shall notify the board and	84
the maternity home in writing of the director's action not later	85
than forty-five days after the decision to void.	86

Sec. 3711.30.  (A) As used in this section, "opioid" means	87
opium, opium derivatives, and synthetic opium substitutes.	88

(B) Each maternity unit, newborn care nursery, and maternity	89
home shall report to the department of health the number of	90
newborns born to residents of this state in the unit, nursery, or	91
home during the preceding calendar quarter that were diagnosed as	92
opioid dependent at birth. The reports shall be submitted not	93
later than thirty days after the end of each quarter and shall not	94
include any patient-identifying information.	95

(C) The department shall establish standards and procedures	96
for reporting the information required by this section. The	97
information reported under this section shall not be used for law	98
enforcement purposes or disclosed to law enforcement authorities.	99

(D) The department shall compile the information submitted	100
under this section and make a summary of that information	101
available to the public not later than ninety days after the end	102
of each calendar year.	103

Sec. 3719.41.  Controlled substance schedules I, II, III, IV,	104
and V are hereby established, which schedules include the	105
following, subject to amendment pursuant to section 3719.43 or	106
3719.44 of the Revised Code.	107

SCHEDULE I	108

(A) Narcotics-opiates

109

Any of the following opiates, including their isomers,	110
esters, ethers, salts, and salts of isomers, esters, and ethers,	111
unless specifically excepted under federal drug abuse control	112
laws, whenever the existence of these isomers, esters, ethers, and	113
salts is possible within the specific chemical designation:	114

(1) Acetyl-alpha-methylfentanyl	115
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);	116

(2) Acetylmethadol;

117

(3) Allylprodine;

118

(4) Alphacetylmethadol (except levo-alphacetylmethadol, also	119
known as levo-alpha-acetylmethadol, levomethadyl acetate, or	120
LAAM);	121

(5) Alphameprodine;

122

(6) Alphamethadol;

123

(7) Alpha-methylfentanyl	124
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide;	125
1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);	126

(8) Alpha-methylthiofentanyl	127
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-	128
phenylpropanamide);	129

(9) Benzethidine;

130

(10) Betacetylmethadol;

131

(11) Beta-hydroxyfentanyl	132
(N-[1-(2-hydroxy-2-phenethyl-4-piperidinyl]-N- phenylpropanamide);	133

(12) Beta-hydroxy-3-methylfentanyl (other name:	134
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-	135
phenylpropanamide);	136

(13) Betameprodine;

137

(14) Betamethadol;

138

(15) Betaprodine;

139

(16) Clonitazene;

140

(17) Dextromoramide;

141

(18) Diampromide;

142

(19) Diethylthiambutene;

143

(20) Difenoxin;

144

(21) Dimenoxadol;

145

(22) Dimepheptanol;

146

(23) Dimethylthiambutene;

147

(24) Dioxaphetyl butyrate;

148

(25) Dipipanone;

149

(26) Ethylmethylthiambutene;

150

(27) Etonitazene;

151

(28) Etoxeridine;

152

(29) Furethidine;

153

(30) Hydroxypethidine;

154

(31) Ketobemidone;

155

(32) Levomoramide;

156

(33) Levophenacylmorphan;

157

(34) 3-methylfentanyl	158
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N- phenylpropanamide);	159

(35) 3-methylthiofentanyl	160
(N-[3-methyl-1-[2-(thienyl)ethyl]-4-piperidinyl]-N-	161
phenylpropanamide);	162

(36) Morpheridine;

163

(37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

164

(38) Noracymethadol;

165

(39) Norlevorphanol;

166

(40) Normethadone;

167

(41) Norpipanone;

168

(42) Para-fluorofentanyl	169
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide;	170

(43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;

171

(44) Phenadoxone;

172

(45) Phenampromide;

173

(46) Phenomorphan;

174

(47) Phenoperidine;

175

(48) Piritramide;

176

(49) Proheptazine;

177

(50) Properidine;

178

(51) Propiram;

179

(52) Racemoramide;

180

(53) Thiofentanyl	181
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide;	182

(54) Tilidine;

183

(55) Trimeperidine.

184

(B) Narcotics-opium derivatives

185

Any of the following opium derivatives, including their	186
salts, isomers, and salts of isomers, unless specifically excepted	187
under federal drug abuse control laws, whenever the existence of	188
these salts, isomers, and salts of isomers is possible within the	189
specific chemical designation:	190

(1) Acetorphine;

191

(2) Acetyldihydrocodeine;

192

(3) Benzylmorphine;

193

(4) Codeine methylbromide;

194

(5) Codeine-n-oxide;

195

(6) Cyprenorphine;

196

(7) Desomorphine;

197

(8) Dihydromorphine;

198

(9) Drotebanol;

199

(10) Etorphine (except hydrochloride salt);

200

(11) Heroin;

201

(12) Hydromorphinol;

202

(13) Methyldesorphine;

203

(14) Methyldihydromorphine;

204

(15) Morphine methylbromide;

205

(16) Morphine methylsulfonate;

206

(17) Morphine-n-oxide;

207

(18) Myrophine;

208

(19) Nicocodeine;

209

(20) Nicomorphine;

210

(21) Normorphine;

211

(22) Pholcodine;

212

(23) Thebacon.

213

(C) Hallucinogens

214

Any material, compound, mixture, or preparation that contains	215
any quantity of the following hallucinogenic substances, including	216
their salts, isomers, and salts of isomers, unless specifically	217
excepted under federal drug abuse control laws, whenever the	218
existence of these salts, isomers, and salts of isomers is	219
possible within the specific chemical designation. For the	220
purposes of this division only, "isomer" includes the optical	221
isomers, position isomers, and geometric isomers.	222

(1) Alpha-ethyltryptamine (some trade or other names:	223
etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine;	224
3-(2-aminobutyl) indole; alpha-ET; and AET);	225

(2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other	226
names: 4-bromo-2,5-dimethoxy-alpha-methyphenethylamine;	227
4-bromo-2,5-DMA);	228

(3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other	229
names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;	230
alpha-desmethyl DOB; 2C-B, Nexus);	231

(4) 2,5-dimethoxyamphetamine (some trade or other names:	232
2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);	233

(5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other	234
names: DOET);	235

(6) 4-methoxyamphetamine (some trade or other names:	236
4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine;	237
PMA);	238

(7) 5-methoxy-3,4-methylenedioxy-amphetamine;

239

(8) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other	240
names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM"	241
and "STP");	242

(9) 3,4-methylenedioxy amphetamine (MDA);

243

(10) 3,4-methylenedioxymethamphetamine (MDMA);

244

(11) 3,4-methylenedioxy-N-ethylamphetamine (also known as	245
N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl	246
MDA, MDE, MDEA);	247

(12) N-hydroxy-3,4-methylenedioxyamphetamine (also known as	248
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine and	249
N-hydroxy MDA);	250

(13) 3,4,5-trimethoxy amphetamine;

251

(14) Bufotenine (some trade or other names:	252
3-(beta-dimethylaminoethyl)-5-hydroxyindole;	253
3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin;	254
5-hydroxy-N, N-dimethyltryptamine; mappine);	255

(15) Diethyltryptamine (some trade or other names: N,	256
N-diethyltryptamine; DET);	257

(16) Dimethyltryptamine (some trade or other names: DMT);

258

(17) Ibogaine (some trade or other names:	259
7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-	260
5H-pyrido[1',2':1,2] azepino [5, 4-b] indole; tabernanthe iboga);	261

(18) Lysergic acid diethylamide;

262

(19) Marihuana;

263

(20) Mescaline;

264

(21) Parahexyl (some trade or other names: 3-hexyl-1-	265
hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;	266
synhexyl);	267

(22) Peyote (meaning all parts of the plant presently	268
classified botanically as "Lophophora williamsii Lemaire," whether	269
growing or not, the seeds of that plant, any extract from any part	270
of that plant, and every compound, manufacture, salts, derivative,	271
mixture, or preparation of that plant, its seeds, or its	272
extracts);	273

(23) N-ethyl-3-piperidyl benzilate;

274

(24) N-methyl-3-piperidyl benzilate;

275

(25) Psilocybin;

276

(26) Psilocyn;

277

(27) Tetrahydrocannabinols (synthetic equivalents of the	278
substances contained in the plant, or in the resinous extractives	279
of Cannabis, sp. and/or synthetic substances, derivatives, and	280
their isomers with similar chemical structure and pharmacological	281
activity such as the following: delta-1-cis or trans	282
tetrahydrocannabinol, and their optical isomers; delta-6-cis or	283
trans tetrahydrocannabinol, and their optical isomers;	284
delta-3,4-cis or trans tetrahydrocannabinol, and its optical	285
isomers. (Since nomenclature of these substances is not	286
internationally standardized, compounds of these structures,	287
regardless of numerical designation of atomic positions, are	288
covered.));	289

(28) Ethylamine analog of phencyclidine (some trade or other	290
names: N-ethyl-1-phenylcyclohexylamine;	291
(1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;	292
cyclohexamine; PCE);	293

(29) Pyrrolidine analog of phencyclidine (some trade or other	294
names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP);	295

(30) Thiophene analog of phencyclidine (some trade or other	296
names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog	297
of phencyclidine; TPCP; TCP);	298

(31) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

299

(32) Hashish;

300

(33) Salvia divinorum;

301

(34) Salvinorin A;

302

(35)	303
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone	304
(UR-144);	305

(36) 1-pentyl-3-(1-adamantoyl)indole (AB-001);

306

(37) N-adamantyl-1-pentylindole-3-carboxamide;

307

(38) N-adamantyl-1-pentylindazole-3-carboxamide (AKB48);

308

(39) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone	309
(methoxetamine);	310

(40) N,N-diallyl-5-methoxytryptamine (5MeO-DALT);

311

(41)	312
[1-(5-fluoropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone	313
(5-fluoropentyl-UR-144; XLR11);	314

(42)	315
[1-(5-chloropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone	316
(5-chloropentyl-UR-144);	317

(43)	318
[1-(5-bromopentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone	319
(5-bromopentyl-UR-144);	320

(44)	321
{1-[2-(4-morpholinyl)ethyl]indol-3-yl}-(2,2,3,3-tetramethylcyclopropyl)	322
methanone (A-796,260);	323

(45)	324
1-[(N-methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole	325
(AM1248);	326

(46) N-adamantyl-1-(5-fluoropentylindole)-3-carboxamide;

327

(47) 5-(2-aminopropyl)benzofuran (5-APB);

328

(48) 6-(2-aminopropyl)benzofuran (6-APB);

329

(49) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB);

330

(50) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB);

331

(51) Benzothiophenylcyclohexylpiperidine (BTCP);

332

(52) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

333

(53) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

334

(54) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

335

(55) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

336

(56) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine	337
(2C-T-2);	338

(57) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine	339
(2C-T-4);	340

(58) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

341

(59) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

342

(60) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

343

(61) 4-methoxymethamphetamine (PMMA);

344

(62) 5,6 - Methylenedioxy-2-aminoindane (MDAI);

345

(63) 5-iodo-2-aminoindiane (5-IAI);

346

(64) 2-(4-iodo-2,5-dimethoxyphenyl)-N-	347
[(2-methoxyphenyl)methyl]ethanamine(25I-NBOMe);	348

(65) Diphenylprolinol (diphenyl(pyrrolidin-2-yl)methanol,	349
D2PM);	350

(66) Desoxypipradrol (2-benzhydrylpiperidine);

351

(67) Synthetic cannabinoids - unless specifically excepted or	352
unless listed in another schedule, any material, compound,	353
mixture, or preparation that contains any quantity of a synthetic	354
cannabinoid found to be in any of the following chemical groups or	355
any of those groups which contain any synthetic cannabinoid salts,	356
isomers, or salts of isomers, whenever the existence of such	357
salts, isomers, or salts of isomers is possible within the	358
specific chemical groups:	359

(a) Naphthoylindoles: any compound containing a	360
3-(1-naphthoyl)indole structure with or without substitution at	361
the nitrogen atom of the indole ring by an alkyl, haloalkyl,	362
alkenyl, cycloalkylmethyl, cycloalkylethyl,	363
(N-methylpiperidin-2-yl)methyl, cyanoalkyl,	364
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl,	365
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group,	366
whether or not further substituted on the indole ring to any	367
extent or whether or not substituted on the naphthyl group to any	368
extent. Naphthoylindoles include, but are not limited to,	369
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);	370
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),	371
1-pentyl-3-(1-naphthoyl)indole (JWH-018), and	372
1-butyl-3-(1-naphthoyl)indole (JWH-073).	373

(b) Naphthylmethylindoles: any compound containing a	374
1H-indol-3-yl-(1-naphthyl)methane structure with or without	375
substitution at the nitrogen atom of the indole ring by an alkyl,	376
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,	377
(N-methylpiperidin-2-yl)methyl, cyanoalkyl,	378
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl,	379
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group,	380
whether or not further substituted on the indole ring to any	381
extent or whether or not substituted on the naphthyl group to any	382
extent. Naphthylmethylindoles include, but are not limited to,	383
(1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175).	384

(c) Naphthoylpyrroles: any compound containing a	385
3-(1-naphthoyl)pyrrole structure with or without substitution at	386
the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,	387
alkenyl, cycloalkylmethyl, cycloalkylethyl,	388
(N-methylpiperidin-2-yl)methyl, cyanoalkyl,	389
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl,	390
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group,	391
whether or not further substituted on the pyrrole ring to any	392
extent or whether or not substituted on the naphthyl group to any	393
extent. Naphthoylpyrroles include, but are not limited to,	394
1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147).	395

(d) Naphthylmethylindenes: any compound containing a	396
naphthylmethylideneindene structure with or without substitution	397
at the 3-position of the indene ring by an alkyl, haloalkyl,	398
alkenyl, cycloalkylmethyl, cycloalkylethyl,	399
(N-methylpiperidin-2-yl)methyl, cyanoalkyl,	400
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl,	401
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group,	402
whether or not further substituted on the indene group to any	403
extent or whether or not substituted on the naphthyl group to any	404
extent. Naphthylmethylindenes include, but are not limited to,	405
(1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176).	406

(e) Phenylacetylindoles: any compound containing a	407
3-phenylacetylindole structure with or without substitution at the	408
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,	409
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl,	410
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,	411
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or	412
2-(4-morpholinyl)ethyl group, whether or not further substituted	413
on the indole ring to any extent or whether or not substituted on	414
the phenyl group to any extent. Phenylacetylindoles include, but	415
are not limited to, 1-pentyl-3-(2-methoxyphenylacetyl)indole	416
(JWH-250), and	417
1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);	418
1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).	419

(f) Cyclohexylphenols: any compound containing a	420
2-(3-hydroxycyclohexyl)phenol structure with or without	421
substitution at the 5-position of the phenolic ring by an alkyl,	422
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,	423
(N-methylpiperidin-2-yl)methyl, cyanoalkyl,	424
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl,	425
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group,	426
whether or not further substituted on the cyclohexyl group to any	427
extent. Cyclohexylphenols include, but are not limited to,	428
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	429
(some trade or other names: CP-47,497) and	430
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (some	431
trade or other names: cannabicyclohexanol; CP-47,497 C8	432
homologue).	433

(g) Benzoylindoles: any compound containing a 3-(1-naphthoyl	434
1-benzoyl)indole structure with or without substitution at the	435
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,	436
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl,	437
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,	438
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl or	439
2-(4-morpholinyl)ethyl group, whether or not further substituted	440
on the indole ring to any extent or whether or not substituted on	441
the phenyl group to any extent. Benzoylindoles include, but are	442
not limited to, 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),	443
1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole	444
(Pravadoline or WIN 48, 098).	445

(D) Depressants

446

Any material, compound, mixture, or preparation that contains	447
any quantity of the following substances having a depressant	448
effect on the central nervous system, including their salts,	449
isomers, and salts of isomers, unless specifically excepted under	450
federal drug abuse control laws, whenever the existence of these	451
salts, isomers, and salts of isomers is possible within the	452
specific chemical designation:	453

(1) Mecloqualone;

454

(2) Methaqualone.

455

(E) Stimulants

456

Unless specifically excepted or unless listed in another	457
schedule, any material, compound, mixture, or preparation that	458
contains any quantity of the following substances having a	459
stimulant effect on the central nervous system, including their	460
salts, isomers, and salts of isomers:	461

(1) Aminorex (some other names: aminoxaphen;	462
2-amino-5-phenyl-2-oxazoline; or	463
4,5-dihydro-5-phenyl-2-oxazolamine);	464

(2) Fenethylline;

465

(3) (+/-)cis-4-methylaminorex	466
((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);	467

(4) N-ethylamphetamine;

468

(5) N,N-dimethylamphetamine (also known as	469
N,N-alpha-trimethyl-benzeneethanamine;	470
N,N-alpha-trimethylphenethylamine);	471

(6) N-methyl-1-(thiophen-2-yl) propan-2-amine	472
(Methiopropamine);	473

(7) Substituted cathinones - any compound except bupropion or	474
compounds listed under a different schedule, structurally derived	475
from 2-aminopropan-1-one by substitution at the 1-position with	476
either phenyl, naphthyl, or thiophene ring systems, whether or not	477
the compound is further modified in any of the following ways:	478

(a) By substitution in the ring system to any extent with	479
alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide	480
substituents, whether or not further substituted in the ring	481
system by one or more other univalent substituents;	482

(b) By substitution at the 3-position with an acyclic alkyl	483
substituent;	484

(c) By substitution at the 2-amino nitrogen atom with alkyl,	485
dialkyl, benzyl, or methoxybenzyl groups;	486

(d) By inclusion of the 2-amino nitrogen atom in a cyclic	487
structure.	488

Examples of substituted cathinones include, but are not	489
limited to, methylone (3,4-methylenedioxymethcathinone), MDPV	490
(3,4-methylenedioxypyrovalerone), mephedrone	491
(4-methylmethcathinone), 4-methoxymethcathinone,	492
4-fluoromethcathinone, 3-fluoromethcathinone, Pentedrone	493
(2-(methylamino)-1-phenyl-1-pentanone), pentylone	494
(1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone),	495
2-(1-pyrrolidinyl)-1-(4-methylphenyl)-1-propanone, alpha-PVP	496
(1-phenyl-2-(1-pyrrodinyl)-1-pentanone), cathinone	497
(2-amino-1-phenyl-1-propanone), and methcathinone	498
(2-(methylamino)-propiophenone).	499

SCHEDULE II	500

(A) Narcotics-opium and opium derivatives

501

Unless specifically excepted under federal drug abuse control	502
laws or unless listed in another schedule, any of the following	503
substances whether produced directly or indirectly by extraction	504
from substances of vegetable origin, independently by means of	505
chemical synthesis, or by a combination of extraction and chemical	506
synthesis:	507

(1) Opium and opiate, and any salt, compound, derivative, or	508
preparation of opium or opiate, excluding apomorphine,	509
thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,	510
naloxone, and naltrexone, and their respective salts, but	511
including the following:	512

(a) Raw opium;

513

(b) Opium extracts;

514

(c) Opium fluid extracts;

515

(d) Powdered opium;

516

(e) Granulated opium;

517

(f) Tincture of opium;

518

(g) Codeine;

519

(h) Ethylmorphine;

520

(i) Etorphine hydrochloride;

521

(j) Hydrocodone;

522

(k) Hydromorphone;

523

(l) Metopon;

524

(m) Morphine;

525

(n) Oxycodone;

526

(o) Oxymorphone;

527

(p) Thebaine.

528

(2) Any salt, compound, derivative, or preparation thereof	529
that is chemically equivalent to or identical with any of the	530
substances referred to in division (A)(1) of this schedule, except	531
that these substances shall not include the isoquinoline alkaloids	532
of opium;	533

(3) Opium poppy and poppy straw;

534

(4) Coca leaves and any salt, compound, derivative, or	535
preparation of coca leaves (including cocaine and ecgonine, their	536
salts, isomers, and derivatives, and salts of those isomers and	537
derivatives), and any salt, compound, derivative, or preparation	538
thereof that is chemically equivalent to or identical with any of	539
these substances, except that the substances shall not include	540
decocainized coca leaves or extraction of coca leaves, which	541
extractions do not contain cocaine or ecgonine;	542

(5) Concentrate of poppy straw (the crude extract of poppy	543
straw in either liquid, solid, or powder form that contains the	544
phenanthrene alkaloids of the opium poppy).	545

(B) Narcotics-opiates

546

Unless specifically excepted under federal drug abuse control	547
laws or unless listed in another schedule, any of the following	548
opiates, including their isomers, esters, ethers, salts, and salts	549
of isomers, esters, and ethers, whenever the existence of these	550
isomers, esters, ethers, and salts is possible within the specific	551
chemical designation, but excluding dextrorphan and	552
levopropoxyphene:	553

(1) Alfentanil;

554

(2) Alphaprodine;

555

(3) Anileridine;

556

(4) Bezitramide;

557

(5) Bulk dextropropoxyphene (non-dosage forms);

558

(6) Carfentanil;

559

(7) Dihydrocodeine;

560

(8) Diphenoxylate;

561

(9) Fentanyl;

562

(10) Isomethadone;

563

(11) Levo-alphacetylmethadol (some other names:	564
levo-alpha-acetylmethadol; levomethadyl acetate; LAAM);	565

(12) Levomethorphan;

566

(13) Levorphanol;

567

(14) Metazocine;

568

(15) Methadone;

569

(16) Methadone-intermediate,	570
4-cyano-2-dimethylamino-4,4-diphenyl butane;	571

(17) Moramide-intermediate,	572
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;	573

(18) Pethidine (meperidine);

574

(19) Pethidine-intermediate-A,	575
4-cyano-1-methyl-4-phenylpiperidine;	576

(20) Pethidine-intermediate-B,	577
ethyl-4-phenylpiperidine-4-carboxylate;	578

(21) Pethidine-intermediate-C,	579
1-methyl-4-phenylpiperidine-4-carboxylic acid;	580

(22) Phenazocine;

581

(23) Piminodine;

582

(24) Racemethorphan;

583

(25) Racemorphan;

584

(26) Remifentanil;

585

(27) Sufentanil.

586

(C) Stimulants

587

Unless specifically excepted under federal drug abuse control	588
laws or unless listed in another schedule, any material, compound,	589
mixture, or preparation that contains any quantity of the	590
following substances having a stimulant effect on the central	591
nervous system:	592

(1) Amphetamine, its salts, its optical isomers, and salts of	593
its optical isomers;	594

(2) Methamphetamine, its salts, its isomers, and salts of its	595
isomers;	596

(3) Methylphenidate;

597

(4) Phenmetrazine and its salts.

598

(D) Depressants

599

Unless specifically excepted under federal drug abuse control	600
laws or unless listed in another schedule, any material, compound,	601
mixture, or preparation that contains any quantity of the	602
following substances having a depressant effect on the central	603
nervous system, including their salts, isomers, and salts of	604
isomers, whenever the existence of these salts, isomers, and salts	605
of isomers is possible within the specific chemical designation:	606

(1) Amobarbital;

607

(2) Gamma-hydroxy-butyrate;

608

(3) Glutethimide;

609

(4) Pentobarbital;

610

(5) Phencyclidine (some trade or other names:	611
1-(1-phenylcyclohexyl)piperidine; PCP);	612

(6) Secobarbital;

613

(7) 1-aminophenylcyclohexane and all N-mono-substituted	614
and/or all N-N-disubstituted analogs including, but not limited	615
to, the following:	616

(a) 1-phenylcyclohexylamine;

617

(b) (1-phenylcyclohexyl) methylamine;

618

(c) (1-phenylcyclohexyl) dimethylamine;

619

(d) (1-phenylcyclohexyl) methylethylamine;

620

(e) (1-phenylcyclohexyl) isopropylamine;

621

(f) 1-(1-phenylcyclohexyl) morpholine.

622

(E) Hallucinogenic substances

623

(1) Nabilone (another name for nabilone:	624
(+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-	625
hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one).	626

(F) Immediate precursors

627

Unless specifically excepted under federal drug abuse control	628
laws or unless listed in another schedule, any material, compound,	629
mixture, or preparation that contains any quantity of the	630
following substances:	631

(1) Immediate precursor to amphetamine and methamphetamine:

632

(a) Phenylacetone (some trade or other names:	633
phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl	634
ketone);	635

(2) Immediate precursors to phencyclidine (PCP):

636

(a) 1-phenylcyclohexylamine;

637

(b) 1-piperidinocyclohexanecarbonitrile (PCC).

638

SCHEDULE III	639

(A) Stimulants

640

Unless specifically excepted under federal drug abuse control	641
laws or unless listed in another schedule, any material, compound,	642
mixture, or preparation that contains any quantity of the	643
following substances having a stimulant effect on the central	644
nervous system, including their salts, their optical isomers,	645
position isomers, or geometric isomers, and salts of these	646
isomers, whenever the existence of these salts, isomers, and salts	647
of isomers is possible within the specific chemical designation:	648

(1) All stimulant compounds, mixtures, and preparations	649
included in schedule III pursuant to the federal drug abuse	650
control laws and regulations adopted under those laws;	651

(2) Benzphetamine;

652

(3) Chlorphentermine;

653

(4) Clortermine;

654

(5) Phendimetrazine.

655

(B) Depressants

656

Unless specifically excepted under federal drug abuse control	657
laws or unless listed in another schedule, any material, compound,	658
mixture, or preparation that contains any quantity of the	659
following substances having a depressant effect on the central	660
nervous system:	661

(1) Any compound, mixture, or preparation containing	662
amobarbital, secobarbital, pentobarbital, or any salt of any of	663
these drugs, and one or more other active medicinal ingredients	664
that are not listed in any schedule;	665

(2) Any suppository dosage form containing amobarbital,	666
secobarbital, pentobarbital, or any salt of any of these drugs and	667
approved by the food and drug administration for marketing only as	668
a suppository;	669

(3) Any substance that contains any quantity of a derivative	670
of barbituric acid or any salt of a derivative of barbituric acid;	671

(4) Chlorhexadol;

672

(5) Ketamine, its salts, isomers, and salts of isomers (some	673
other names for ketamine:	674
(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);	675

(6) Lysergic acid;

676

(7) Lysergic acid amide;

677

(8) Methyprylon;

678

(9) Sulfondiethylmethane;

679

(10) Sulfonethylmethane;

680

(11) Sulfonmethane;

681

(12) Tiletamine, zolazepam, or any salt of tiletamine or	682
zolazepam (some trade or other names for a tiletamine-zolazepam	683
combination product: Telazol); (some trade or other names for	684
tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some	685
trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-	686
dihydro-1,3,8-trimethylpyrazolo-[3, 4-e][1,4]-diazepin-7(1H)-one;	687
flupyrazapon).	688

(C) Narcotic antidotes

689

(1) Nalorphine.

690

(D) Narcotics-narcotic preparations

691

Unless specifically excepted under federal drug abuse control	692
laws or unless listed in another schedule, any material, compound,	693
mixture, or preparation that contains any of the following	694
narcotic drugs, or their salts calculated as the free anhydrous	695
base or alkaloid, in limited quantities as set forth below:	696

(1) Not more than 1.8 grams of codeine per 100 milliliters or	697
not more than 90 milligrams per dosage unit, with an equal or	698
greater quantity of an isoquinoline alkaloid of opium;	699

(2) Not more than 1.8 grams of codeine per 100 milliliters or	700
not more than 90 milligrams per dosage unit, with one or more	701
active, nonnarcotic ingredients in recognized therapeutic amounts;	702

(3) Not more than 300 milligrams of dihydrocodeinone per 100	703
milliliters or not more than 15 milligrams per dosage unit, with a	704
fourfold or greater quantity of an isoquinoline alkaloid of opium;	705

(4) Not more than 300 milligrams of dihydrocodeinone per 100	706
milliliters or not more than 15 milligrams per dosage unit, with	707
one or more active, nonnarcotic ingredients in recognized	708
therapeutic amounts;	709

(5) Not more than 1.8 grams of dihydrocodeine per 100	710
milliliters or not more than 90 milligrams per dosage unit, with	711
one or more active, nonnarcotic ingredients in recognized	712
therapeutic amounts;	713

(6) Not more than 300 milligrams of ethylmorphine per 100	714
milliliters or not more than 15 milligrams per dosage unit, with	715
one or more active, nonnarcotic ingredients in recognized	716
therapeutic amounts;	717

(7) Not more than 500 milligrams of opium per 100 milliliters	718
or per 100 grams or not more than 25 milligrams per dosage unit,	719
with one or more active, nonnarcotic ingredients in recognized	720
therapeutic amounts;	721

(8) Not more than 50 milligrams of morphine per 100	722
milliliters or per 100 grams, with one or more active, nonnarcotic	723
ingredients in recognized therapeutic amounts.	724

(E) Anabolic steroids

725

Unless specifically excepted under federal drug abuse control	726
laws or unless listed in another schedule, any material, compound,	727
mixture, or preparation that contains any quantity of the	728
following substances, including their salts, esters, isomers, and	729
salts of esters and isomers, whenever the existence of these	730
salts, esters, and isomers is possible within the specific	731
chemical designation:	732

(1) Anabolic steroids. Except as otherwise provided in	733
division (E)(1) of schedule III, "anabolic steroids" means any	734
drug or hormonal substance that is chemically and	735
pharmacologically related to testosterone (other than estrogens,	736
progestins, and corticosteroids) and that promotes muscle growth.	737
"Anabolic steroids" does not include an anabolic steroid that is	738
expressly intended for administration through implants to cattle	739
or other nonhuman species and that has been approved by the United	740
States secretary of health and human services for that	741
administration, unless a person prescribes, dispenses, or	742
distributes this type of anabolic steroid for human use. "Anabolic	743
steroid" includes, but is not limited to, the following:	744

(a) Boldenone;

745

(b) Chlorotestosterone (4-chlortestosterone);

746

(c) Clostebol;

747

(d) Dehydrochlormethyltestosterone;

748

(e) Dihydrotestosterone (4-dihydrotestosterone);

749

(f) Drostanolone;

750

(g) Ethylestrenol;

751

(h) Fluoxymesterone;

752

(i) Formebulone (formebolone);

753

(j) Mesterolone;

754

(k) Methandienone;

755

(l) Methandranone;

756

(m) Methandriol;

757

(n) Methandrostenolone;

758

(o) Methenolone;

759

(p) Methyltestosterone;

760

(q) Mibolerone;

761

(r) Nandrolone;

762

(s) Norethandrolone;

763

(t) Oxandrolone;

764

(u) Oxymesterone;

765

(v) Oxymetholone;

766

(w) Stanolone;

767

(x) Stanozolol;

768

(y) Testolactone;

769

(z) Testosterone;

770

(aa) Trenbolone;

771

(bb) Any salt, ester, isomer, or salt of an ester or isomer	772
of a drug or hormonal substance described or listed in division	773
(E)(1) of schedule III if the salt, ester, or isomer promotes	774
muscle growth.	775

(F) Hallucinogenic substances

776

(1) Dronabinol (synthetic) in sesame oil and encapsulated in	777
a soft gelatin capsule in a United States food and drug	778
administration approved drug product (some other names for	779
dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-	780
6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or	781
(-)-delta-9-(trans)-tetrahydrocannabinol).	782

SCHEDULE IV	783

(A) Narcotic drugs

784

Unless specifically excepted by federal drug abuse control	785
laws or unless listed in another schedule, any material, compound,	786
mixture, or preparation that contains any of the following	787
narcotic drugs, or their salts calculated as the free anhydrous	788
base or alkaloid, in limited quantities as set forth below:	789

(1) Not more than one milligram of difenoxin and not less	790
than 25 micrograms of atropine sulfate per dosage unit;	791

(2) Dextropropoxyphene	792
(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-	793
propionoxybutane)[final dosage forms].	794

(B) Depressants

795

Unless specifically excepted under federal drug abuse control	796
laws or unless listed in another schedule, any material, compound,	797
mixture, or preparation that contains any quantity of the	798
following substances, including their salts, isomers, and salts of	799
isomers, whenever the existence of these salts, isomers, and salts	800
of isomers is possible within the specific chemical designation:	801

(1) Alprazolam;

802

(2) Barbital;

803

(3) Bromazepam;

804

(4) Camazepam;

805

(5) Chloral betaine;

806

(6) Chloral hydrate;

807

(7) Chlordiazepoxide;

808

(8) Clobazam;

809

(9) Clonazepam;

810

(10) Clorazepate;

811

(11) Clotiazepam;

812

(12) Cloxazolam;

813

(13) Delorazepam;

814

(14) Diazepam;

815

(15) Estazolam;

816

(16) Ethchlorvynol;

817

(17) Ethinamate;

818

(18) Ethyl loflazepate;

819

(19) Fludiazepam;

820

(20) Flunitrazepam;

821

(21) Flurazepam;

822

(22) Halazepam;

823

(23) Haloxazolam;

824

(24) Ketazolam;

825

(25) Loprazolam;

826

(26) Lorazepam;

827

(27) Lormetazepam;

828

(28) Mebutamate;

829

(29) Medazepam;

830

(30) Meprobamate;

831

(31) Methohexital;

832

(32) Methylphenobarbital (mephobarbital);

833

(33) Midazolam;

834

(34) Nimetazepam;

835

(35) Nitrazepam;

836

(36) Nordiazepam;

837

(37) Oxazepam;

838

(38) Oxazolam;

839

(39) Paraldehyde;

840

(40) Petrichloral;

841

(41) Phenobarbital;

842

(42) Pinazepam;

843

(43) Prazepam;

844

(44) Quazepam;

845

(45) Temazepam;

846

(46) Tetrazepam;

847

(47) Triazolam;

848

(48) Zaleplon;

849

(49) Zolpidem.

850

(C) Fenfluramine

851

Any material, compound, mixture, or preparation that contains	852
any quantity of the following substances, including their salts,	853
their optical isomers, position isomers, or geometric isomers, and	854
salts of these isomers, whenever the existence of these salts,	855
isomers, and salts of isomers is possible within the specific	856
chemical designation:	857

(1) Fenfluramine.

858

(D) Stimulants

859

Unless specifically excepted under federal drug abuse control	860
laws or unless listed in another schedule, any material, compound,	861
mixture, or preparation that contains any quantity of the	862
following substances having a stimulant effect on the central	863
nervous system, including their salts, their optical isomers,	864
position isomers, or geometric isomers, and salts of these	865
isomers, whenever the existence of these salts, isomers, and salts	866
of isomers is possible within the specific chemical designation:	867

(1) Cathine ((+)-norpseudoephedrine);

868

(2) Diethylpropion;

869

(3) Fencamfamin;

870

(4) Fenproporex;

871

(5) Mazindol;

872

(6) Mefenorex;

873

(7) Modafinil;

874

(8) Pemoline (including organometallic complexes and chelates	875
thereof);	876

(9) Phentermine;

877

(10) Pipradrol;

878

(11) Sibutramine;

879

(12) SPA [(-)-1-dimethylamino-1,2-diphenylethane].

880

(E) Other substances

881

Unless specifically excepted under federal drug abuse control	882
laws or unless listed in another schedule, any material, compound,	883
mixture, or preparation that contains any quantity of the	884
following substances, including their salts:	885

(1) Pentazocine;

886

(2) Butorphanol (including its optical isomers).

887

SCHEDULE V	888

(A) Narcotic drugs

889

Unless specifically excepted under federal drug abuse control	890
laws or unless listed in another schedule, any material, compound,	891
mixture, or preparation that contains any of the following	892
narcotic drugs, and their salts, as set forth below:	893

(1) Buprenorphine.

894

(B) Narcotics-narcotic preparations

895

Narcotic drugs containing non-narcotic active medicinal	896
ingredients. Any compound, mixture, or preparation that contains	897
any of the following narcotic drugs, or their salts calculated as	898
the free anhydrous base or alkaloid, in limited quantities as set	899
forth below, and that includes one or more nonnarcotic active	900
medicinal ingredients in sufficient proportion to confer upon the	901
compound, mixture, or preparation valuable medicinal qualities	902
other than those possessed by narcotic drugs alone:	903

(1) Not more than 200 milligrams of codeine per 100	904
milliliters or per 100 grams;	905

(2) Not more than 100 milligrams of dihydrocodeine per 100	906
milliliters or per 100 grams;	907

(3) Not more than 100 milligrams of ethylmorphine per 100	908
milliliters or per 100 grams;	909

(4) Not more than 2.5 milligrams of diphenoxylate and not	910
less than 25 micrograms of atropine sulfate per dosage unit;	911

(5) Not more than 100 milligrams of opium per 100 milliliters	912
or per 100 grams;	913

(6) Not more than 0.5 milligram of difenoxin and not less	914
than 25 micrograms of atropine sulfate per dosage unit.	915

(C) Stimulants

916

Unless specifically exempted or excluded under federal drug	917
abuse control laws or unless listed in another schedule, any	918
material, compound, mixture, or preparation that contains any	919
quantity of the following substances having a stimulant effect on	920
the central nervous system, including their salts, isomers, and	921
salts of isomers:	922

(1) Ephedrine, except as provided in division (K) of section	923
3719.44 of the Revised Code;	924

(2) Pyrovalerone.

925

Section 2.  That existing sections 3711.12 and 3719.41 of the	926
Revised Code are hereby repealed.	927